---
title: "AtriClip LAA exclusion system granted approval for marketing in China"
date: "2024-07-24T08:36:30.000Z"
publishedDate: "24 juillet 2024"
summary: "AtriCure has received regulatory approval from the National Medical Products Administration (NMPA) of China to market and sell several models of its AtriClip left atrial appendage (LAA) exclusion system. The AtriClip device is designed to exclude and electrically isolate the left atrial appendage during cardiac surgery."
importance: ""
sourceUrl: "https://cardiovascularnews.com/atriclip-china-approval/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-07-24-atriclip-laa-exclusion-system-granted-approval-for-marketing-in-china"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/07/AtriClip-web.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/atriclip-china-approval/"
---

![AtriClip LAA exclusion system granted approval for marketing in China](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/07/AtriClip-web.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/atriclip-china-approval/*

## L’essentiel

AtriCure has received regulatory approval from the National Medical Products Administration (NMPA) of China to market and sell several models of its AtriClip left atrial appendage (LAA) exclusion system. The AtriClip device is designed to exclude and electrically isolate the left atrial appendage during cardiac surgery.

## Lien source

https://cardiovascularnews.com/atriclip-china-approval/
